{"id":"W3194931521","doi":"10.1016/s1474-4422(21)00237-4","title":"Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; McGill University; NeuroRx Research (Canada)","funders":"National Institutes of Health; Sanofi","keywords":"Medicine; Multiple sclerosis; Placebo; Cohort; Internal medicine; Interferon beta-1a; Pathology; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002538554,0.0002991903,0.001954889,0.0001833872,0.0001753148,0.00003314712,0.0002400206,0.0001822582,0.00006781048],"category_scores_gemma":[0.003976846,0.0002063319,0.0002025487,0.0003827613,0.00044551,0.00009448964,0.0002243454,0.0008580156,0.000004615821],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002779682,"about_ca_system_score_gemma":0.0002215239,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001223612,"about_ca_topic_score_gemma":0.0006857633,"domain_scores_codex":[0.9957038,0.001589288,0.0009463626,0.000626206,0.0004205581,0.0007137903],"domain_scores_gemma":[0.9946043,0.004090414,0.0002417925,0.0007247104,0.0001564919,0.0001822725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9389874,0.001239651,0.001445214,0.0000537279,0.0002099849,0.0001141009,0.0008183321,0.00009830003,0.05214954,0.00004006827,0.0002641338,0.004579562],"study_design_scores_gemma":[0.9807377,0.002609768,0.008716443,0.000109212,0.0001438203,0.0000584732,0.00009181206,0.003552206,0.003098103,0.00001755846,0.0007063624,0.000158546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796067,0.0008930945,0.00003396969,0.01386673,0.0003811269,0.00476767,0.00002004119,0.0000555669,0.0003750818],"genre_scores_gemma":[0.9959964,0.00120861,0.0001557704,0.001566478,0.000663124,0.0002858085,0.00002953102,0.00003832072,0.00005594694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04905143,"threshold_uncertainty_score":0.8413969,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1181872174142568,"score_gpt":0.3653213659137695,"score_spread":0.2471341484995127,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}